FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000301024> ?p ?o ?g. }

• W2000301024 endingPage "178" @default.
• W2000301024 startingPage "163" @default.
• W2000301024 abstract "Current systemic cytotoxic therapies for cancer are limited by their nonspecific mechanism of action, unwanted toxicities on normal tissues and short-term efficacy due to the emergence of drug resistance. However, identification of the molecular abnormalities in cancer, in particular the key proteins involved in abnormal cell growth, has resulted in various signal transduction inhibitor drugs being developed as new treatment strategies against the disease. Protein farnesyltransferase inhibitors (FTIs) were originally designed to target the Ras signal transduction pathway, although it is now clear that several other intracellular proteins are dependent on post-translational farnesylation (addition of a 15-carbon farnesyl moiety) for their function. Preclinical data revealed that although FTIs inhibit the growth of ras-transformed cells, they are also potent inhibitors of a wide range of cancer cell lines, many of which contain wild type ras. While understanding the mechanism of action of FTIs remains an important research goal, three different FTIs have entered clinical development. Several Phase I trials with each drug have explored different schedules for prolonged administration, and dose-limiting toxicities (DLTs) have varied from myelosuppression, gastrointestinal toxicity and neuropathy. Evidence for anticancer efficacy has come from a number of Phase II studies, not necessarily in tumour types containing ras mutations, which were the initial target for these drugs. Perhaps the most promising use for FTIs will be in combination with conventional cytotoxic drugs, based on preclinical data suggesting synergy, particularly with the taxanes. Clinical combination studies are in progress, and larger Phase II/III clinical trials are planned to see if FTIs can add to the efficacy of conventional therapies." @default.
• W2000301024 created "2016-06-24" @default.
• W2000301024 creator A5031915637 @default.
• W2000301024 creator A5077896405 @default.
• W2000301024 date "2003-05-01" @default.
• W2000301024 modified "2023-09-27" @default.
• W2000301024 title "Protein farnesyltransferase inhibitors" @default.
• W2000301024 cites W1635320150 @default.
• W2000301024 cites W1873121398 @default.
• W2000301024 cites W1884954707 @default.
• W2000301024 cites W1955547739 @default.
• W2000301024 cites W1965995529 @default.
• W2000301024 cites W1975449649 @default.
• W2000301024 cites W1980022529 @default.
• W2000301024 cites W1980827197 @default.
• W2000301024 cites W1982933055 @default.
• W2000301024 cites W1989203819 @default.
• W2000301024 cites W1991760443 @default.
• W2000301024 cites W1992295617 @default.
• W2000301024 cites W2007660746 @default.
• W2000301024 cites W2008431826 @default.
• W2000301024 cites W2009690121 @default.
• W2000301024 cites W2011425688 @default.
• W2000301024 cites W2017098460 @default.
• W2000301024 cites W2036530157 @default.
• W2000301024 cites W2036699032 @default.
• W2000301024 cites W2045369188 @default.
• W2000301024 cites W2051538397 @default.
• W2000301024 cites W2051626784 @default.
• W2000301024 cites W2053956725 @default.
• W2000301024 cites W2054430764 @default.
• W2000301024 cites W2070892171 @default.
• W2000301024 cites W2071124826 @default.
• W2000301024 cites W2071697240 @default.
• W2000301024 cites W2082888699 @default.
• W2000301024 cites W2088428799 @default.
• W2000301024 cites W2090195452 @default.
• W2000301024 cites W2099000660 @default.
• W2000301024 cites W2100147739 @default.
• W2000301024 cites W2127248987 @default.
• W2000301024 cites W2128431291 @default.
• W2000301024 cites W2137343757 @default.
• W2000301024 cites W2141700179 @default.
• W2000301024 cites W2178557511 @default.
• W2000301024 cites W2255894651 @default.
• W2000301024 cites W2324953630 @default.
• W2000301024 cites W4232777855 @default.
• W2000301024 doi "https://doi.org/10.1517/14728214.8.1.163" @default.
• W2000301024 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14610919" @default.
• W2000301024 hasPublicationYear "2003" @default.
• W2000301024 type Work @default.
• W2000301024 sameAs 2000301024 @default.
• W2000301024 citedByCount "22" @default.
• W2000301024 countsByYear W20003010242015 @default.
• W2000301024 countsByYear W20003010242020 @default.
• W2000301024 crossrefType "journal-article" @default.
• W2000301024 hasAuthorship W2000301024A5031915637 @default.
• W2000301024 hasAuthorship W2000301024A5077896405 @default.
• W2000301024 hasConcept C121608353 @default.
• W2000301024 hasConcept C126322002 @default.
• W2000301024 hasConcept C181199279 @default.
• W2000301024 hasConcept C202751555 @default.
• W2000301024 hasConcept C2776120743 @default.
• W2000301024 hasConcept C2777093181 @default.
• W2000301024 hasConcept C2777827897 @default.
• W2000301024 hasConcept C2778396349 @default.
• W2000301024 hasConcept C2778917187 @default.
• W2000301024 hasConcept C2779716203 @default.
• W2000301024 hasConcept C502942594 @default.
• W2000301024 hasConcept C55493867 @default.
• W2000301024 hasConcept C57790582 @default.
• W2000301024 hasConcept C62478195 @default.
• W2000301024 hasConcept C71924100 @default.
• W2000301024 hasConcept C86803240 @default.
• W2000301024 hasConcept C95444343 @default.
• W2000301024 hasConcept C96232424 @default.
• W2000301024 hasConcept C98274493 @default.
• W2000301024 hasConceptScore W2000301024C121608353 @default.
• W2000301024 hasConceptScore W2000301024C126322002 @default.
• W2000301024 hasConceptScore W2000301024C181199279 @default.
• W2000301024 hasConceptScore W2000301024C202751555 @default.
• W2000301024 hasConceptScore W2000301024C2776120743 @default.
• W2000301024 hasConceptScore W2000301024C2777093181 @default.
• W2000301024 hasConceptScore W2000301024C2777827897 @default.
• W2000301024 hasConceptScore W2000301024C2778396349 @default.
• W2000301024 hasConceptScore W2000301024C2778917187 @default.
• W2000301024 hasConceptScore W2000301024C2779716203 @default.
• W2000301024 hasConceptScore W2000301024C502942594 @default.
• W2000301024 hasConceptScore W2000301024C55493867 @default.
• W2000301024 hasConceptScore W2000301024C57790582 @default.
• W2000301024 hasConceptScore W2000301024C62478195 @default.
• W2000301024 hasConceptScore W2000301024C71924100 @default.
• W2000301024 hasConceptScore W2000301024C86803240 @default.
• W2000301024 hasConceptScore W2000301024C95444343 @default.
• W2000301024 hasConceptScore W2000301024C96232424 @default.
• W2000301024 hasConceptScore W2000301024C98274493 @default.
• W2000301024 hasIssue "1" @default.
• W2000301024 hasLocation W20003010241 @default.

• next